

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 December 2005 (01.12.2005)

PCT

(10) International Publication Number
WO 2005/112922 A2

(51) International Patent Classification⁷: A61K 31/416

(21) International Application Number:
PCT/US2005/014131

(22) International Filing Date: 22 April 2005 (22.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/564,636 22 April 2004 (22.04.2004) US
PCT/US2004/015791 20 May 2004 (20.05.2004) US
PCT/US2004/016126 20 May 2004 (20.05.2004) US
60/592,688 30 July 2004 (30.07.2004) US

(71) Applicants (for all designated States except US):
SAMARITAN PHARMACEUTICALS [US/US]; 101
Convention Center Drive, Las Vegas, Nevada 89109 (US).
GEORGETOWN UNIVERSITY [US/US]; Office of
Technology Licensing, Box 571408, Washington, District
of Columbia 20057-1408 (US).

(71) Applicants and


(72) Inventors: LECANU, Laurent [FR/US]; 8370 Greens-
boro Drive, Building #4, Apt. 706, McLean, Virginia
22102 (US). GREESON, Janet [US/US]; 2877 Par-
adise Road, Suite 801, Las Vegas, Nevada 89109 (US).
PAPADOPOULOS, Vassilios [US/US]; 15417 Peach
Leaf Drive, North Potomac, Maryland 20878 (US). XU,
Jing [CN/US]; 14911 Forest Landing Circle, Rockville,
Maryland 20850 (US).

(74) Agents: MCCRACKIN, Ann M. et al.; Schwegman,
Lundberg, Woessner & Kluth, P.A., P.O. Box 2938, Min-
neapolis, Minnesota 55402 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,

[Continued on next page]


(54) Title: BENZAMIDE COMPOUNDS



SP01 (PROCAINE)



SP100 (PROCAINAMIDE)



SP010

(57) Abstract: The invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the infectivity of a pathogen such as a retrovirus toward mammalian cells is implicated and inhibition of its infectivity is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof that inhibits pathogenic infectivity, including pharmaceutically acceptable salts thereof. The invention also provides a therapeutic method for preventing or treating a neuropathological condition or symptom in a mammal, such as human, comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof, including pharmaceutically acceptable salts thereof.

WO 2005/112922 A2